MASON, Ohio--(BUSINESS WIRE)--Oct. 22, 2018--
ATRC), a leading innovator in surgical treatments for atrial
fibrillation (Afib) and left atrial appendage (LAA) management, today
announced that it will be participating in upcoming investor conferences.
AtriCure is scheduled to present at the Stifel 2018 Healthcare
Conference in New York City on Wednesday, November 14, 2018. Management
is scheduled to present at 1:15 p.m. Eastern Time. A live audio webcast
of the presentation may be accessed by visiting the Investors page of
AtriCure’s corporate website at ir.atricure.com.
A replay of the presentation will be available for 90 days following the
AtriCure is scheduled to host investor meetings at the Canaccord Genuity
12th Annual Medical Technologies and Diagnostics Forum in New
York City on Thursday, November 15, 2018.
AtriCure, Inc. provides innovative technologies for the treatment of
Afib and related conditions. Afib affects more than 33 million people
worldwide. Electrophysiologists and cardiothoracic surgeons around the
globe use AtriCure technologies for the treatment of Afib and reduction
of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation
System is the first and only medical device to receive FDA approval for
the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial
Appendage Exclusion System products are the most widely sold LAA
management devices worldwide, with more than 150,000 implanted to date.
For more information, visit AtriCure.com
or follow us on Twitter @AtriCure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181022005858/en/
Source: AtriCure, Inc.
Andy Wade, 513-755-4564
Senior Vice President
and Chief Financial Officer
Lynn Pieper Lewis, 415-937-5402